Published in Vaccine Weekly, August 31st, 2005
According to recent research from New Zealand, "The cellular products obtained following electrofusion (EF) of dendritic cells (DC) and tumor cells have shown promise as cancer vaccines. The immunogenicity of these preparations has been attributed to the presence of small numbers of DC-tumor hybrids and the contribution of the non-hybrid tumor cells present has received little attention. In this report, we investigated the effect of the EF process on the immunogenicity of allogeneic human cells, in particular the colorectal cell line, SW620."
"EF conditions were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly